Behnsawys teamsin vitroresearch showed that Shh induces EMT markers, such as E-cadherin [36]

Behnsawys teamsin vitroresearch showed that Shh induces EMT markers, such as E-cadherin [36]. To sum up, histological data showed that EMT cell phenotype significantly contributes to the occurrence of acquired resistance to tyrosine kinase inhibitors. and more successful than previous therapies – tyrosine kinase inhibitors (TKIs). Up to date, five TKIs have been licensed for ccRCC treatment: sunitinib (SUTENT, Pfizer Inc.), sorafenib (Nexavar, Bayer HealthCare/Onyx Pharmaceuticals), pazopanib (Votrient, GlaxoSmithKline), axitinib (Inlyta, Pfitzer Inc.) and tivozanib (AV-951, AVEO Pharmaceuticals). Researchers have specified different subsets of tyrosine kinase inhibitors potential resistance mechanisms in clear-cell renal cell carcinoma. In most papers published until now, drug resistance is divided into intrinsic SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 and acquired, and typically multi-drug resistance (MDR) protein is described. Herein, the authors focus on molecular analysis concerning acquired, nongenetic resistance SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 to TKIs, with insight into specific biological processes. Keywords:Acquired drug resistance, tyrosine kinase inhibitors, sunitinib, sorafenib, pazopanib, axitinib, tivozanib, epithelial-mesenchymal transition, angiogenic switch, anti-angiogenic therapy, clear-cell renal cell carcinoma, non-genetic resistance mechanisms == Introduction == Clear-cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer in adults and the 10th malignancy worldwide, with approximately 88 400 newly diagnosed patients each year in Europe. Its worldwide incidence and mortality rates rise by 2-3% per decade [1,2]. The etiology of ccRCC is unknown, however obesity, hyper- tension, smoking, unhealthy diet and diabetes are known risk factors [3]. Patients presented with localized ccRCC can be cured with partial or radical nephrectomy. Still, up to 30% of newly diagnosed patients develop metastases and among 20-30% post-surgery treatment cases recurrence is eventually noted. Regardless of the fact that many publications provide insight into SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 the knowledge on probable resistance mechanisms in ccRCC, its actual origin still remains elusive. Lately, therapy for metastatic clear-cell renal cell carcinoma has significantly improved due to the introduction of several novel agents after the failure of initially successful treatment with interleukin 2 (IL-2) or interferon alpha (IFN-), which were both causing severe toxic side effects in many cases [4]. Until a few years ago, immunotherapy was still the only option for metastatic ccRCC treatment. The novel therapies, including tyrosine kinase inhibitors, have been subsequently introduced [1,5,6]. Tyrosine kinases are signaling molecules and prototypic oncogenes, which play an important role in cancer development. They target various kinases including c-KIT, VEGF 1, 2 and 3, PDGFR- and , FLT3, RET, BRAF and CRAF (go to: Abbreviations) [5,6]. TKIs became the most successful class of drugs in the treatment of ccRCC, including sunitinib (SUTENT, Pfizer Inc.), sorafenib (Nexavar, Bayer HealthCare/Onyx Pharmaceuticals), pazopanib (Votrient, GlaxoSmithKline), axitinib (Inlyta, Pfitzer Inc.) and tivozanib (AV-951, AVEO Pharmaceuticals) [5,7-12]. They all primarily function as anti-angiogenic agents, through the inhibition of SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 tumor endothelium growth and tumor cell survival signaling impairment. As multi-targeted agents, they inhibit a number of receptors with varying potency [13]. Tyrosine kinases can be subdivided into two major groups the first one consists of receptor tyrosine kinases (i.e. epithelial growth factor receptor: EGFR, ErbB/HER family members, vascular endothelial growth factor receptor: VEGFR and platelet-derived growth factor receptor: PDGFR) and the second one includes non-receptor cytoplasmic tyrosine kinases (i.e. SRC and FAK) [14]. Receptor tyrosine kinases perform a crucial role in the transduction of extracellular signals into the cell, while non-receptor tyrosine kinases take part mostly in intracellular communication [15]. Vascular endothelial growth factor (VEGF) is an essential molecule in the process of angiogenesis. VEGFR family comprises VEGFR-1, -2, and -3, which all mediate the angiogenic effect of VEGF ligands [16]. There are six different ligands for VEGFR: VEGF-A to VEGFR-E and placental-derived growth factor (PDGF). Those ligands bind to specific receptors on endothelial cells, mostly to VEGFR-2 (FLK-1/KDR), but also to VEGFR-1 (Flt-1) and -3. The binding of VEGF-A to VEGFR-1 is responsible for endothelial cell migration. VEGFR-2 induces endothelial cell proliferation, permeability, and survival and VEGFR-3 is related to lymphangiogenesis Akt3 [17]. The role of endothelium in the process of resistance to TKIs in ccRCC will be described later on. The impact of VEGF on the process of angiogenesis and also on cancer pathogenesis has given the rationale for design and development [16]. TKIs designed mainly for ccRCC therapy operate by four different mechanisms: 1) they compete either with adenosine triphosphate (ATP), or 2) with the substrate, or 3) with both, or 4) they act in an allosteric way [18]. In fact, most small-molecule kinase inhibitors discovered to date compete with ATP. On the basis of chemical and conformational changes, tyrosine kinase inhibitors can be classified into 3 categories. Type I kinase inhibitors recognize the active conformation of a kinase. In contrast, type II kinase inhibitors affect the inactive conformation of a kinase by an indirect competition with ATP. In this way, they.